" TDB-DST Supports Helix Cell Therapeutics under Indo-Singapore Collaboration for Advanced CAR-T Cell Therapy against Multiple Myeloma "

Posted On: 14 MAY 2026 12:34PM by PIB Delhi In a significant step towards strengthening India’s advanced biotechnology and cell therapy ecosystem, the Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has entered into an agreement with M/s Helix Cell Therapeutics Private Limited, Hyderabad, Telangana for the project titled &ldquo;Generation of Novel Dual Targeting Chimeric Antigen Receptor T Cells to Treat Multiple Myeloma and Conducting Phase I Clinical Trial.&rdquo; The project is being implemented under the Indo-Singapore collaborative framework in partnership with Biocell Innovations, Singapore. The project focuses on developing an advanced dual-targeting CAR-T cell therapy for Multiple Myeloma, a debilitating and currently incurable blood cancer. While existing CAR-T therapies targeting BCMA have shown encouraging outcomes in relapsed and refractory patients, the proposed innovation seeks to further improve treatment efficacy and durability of remission by simultaneously targeting both BCMA and CD19 markers expressed on Multiple Myeloma cells. Under the project, Helix Cell Therapeutics will develop, manufacture, and clinically evaluate next-generation dual-targeting CAR-T cells through a Phase I clinical trial. The therapy is intended for patients who have exhausted multiple lines of treatment and currently have limited therapeutic options available. CAR-T cell therapy involves genetically engineering a patient’s own T lymphocytes to specifically identify and destroy cancer cells. The proposed dual-targeting strategy represents a significant advancement over conventional single-marker CAR-T therapies and is expected to improve long-term remission outcomes in difficult-to-treat Multiple Myeloma patients. The project aligns with the Government of India’s vision of strengthening indigenous capabilities in advanced biologics, precision medicine, and next-generation healthcare technologies under the broader framework of Aatmanirbhar Bharat. It also reinforces international technology collaboration between India and Singapore in emerging biomedical innovation sectors. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, &ldquo;Advanced cell and gene therapies represent the future of precision healthcare and hold transformative potential for treating complex and previously incurable diseases. Through this Indo-Singapore collaborative project, TDB is supporting indigenous innovation in advanced immunotherapy platforms that can strengthen India’s global position in next-generation biotechnology and affordable healthcare solutions.&rdquo; A representative from Helix Cell Therapeutics Private Limited expressed gratitude for TDB’s support and stated that the assistance would accelerate clinical translation and commercialization of the company’s innovative CAR-T therapy platform while expanding access to advanced cancer treatment solutions in India. --- For any media inquiries, please reach us at: media-coordinator@tdb.gov.in ******** NKR/FT (Release ID: 2260922) Visitor Counter : 915 Read this release in: हिन्दी , Urdu , Tamil , Telugu Ministry of Science & Technology " TDB-DST Supports Helix Cell Therapeutics under Indo-Singapore Collaboration for Advanced CAR-T Cell Therapy against Multiple Myeloma " Posted On: 14 MAY 2026 12:34PM by PIB Delhi In a significant step towards strengthening India’s advanced biotechnology and cell therapy ecosystem, the Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has entered into an agreement with M/s Helix Cell Therapeutics Private Limited, Hyderabad, Telangana for the project titled &ldquo;Generation of Novel Dual Targeting Chimeric Antigen Receptor T Cells to Treat Multiple Myeloma and Conducting Phase I Clinical Trial.&rdquo; The project is being implemented under the Indo-Singapore collaborative framework in partnership with Biocell Innovations, Singapore. The project focuses on developing an advanced dual-targeting CAR-T cell therapy for Multiple Myeloma, a debilitating and currently incurable blood cancer. While existing CAR-T therapies targeting BCMA have shown encouraging outcomes in relapsed and refractory patients, the proposed innovation seeks to further improve treatment efficacy and durability of remission by simultaneously targeting both BCMA and CD19 markers expressed on Multiple Myeloma cells. Under the project, Helix Cell Therapeutics will develop, manufacture, and clinically evaluate next-generation dual-targeting CAR-T cells through a Phase I clinical trial. The therapy is intended for patients who have exhausted multiple lines of treatment and currently have limited therapeutic options available. CAR-T cell therapy involves genetically engineering a patient’s own T lymphocytes to specifically identify and destroy cancer cells. The proposed dual-targeting strategy represents a significant advancement over conventional single-marker CAR-T therapies and is expected to improve long-term remission outcomes in difficult-to-treat Multiple Myeloma patients. The project aligns with the Government of India’s vision of strengthening indigenous capabilities in advanced biologics, precision medicine, and next-generation healthcare technologies under the broader framework of Aatmanirbhar Bharat. It also reinforces international technology collaboration between India and Singapore in emerging biomedical innovation sectors. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, &ldquo;Advanced cell and gene therapies represent the future of precision healthcare and hold transformative potential for treating complex and previously incurable diseases. Through this Indo-Singapore collaborative project, TDB is supporting indigenous innovation in advanced immunotherapy platforms that can strengthen India’s global position in next-generation biotechnology and affordable healthcare solutions.&rdquo; A representative from Helix Cell Therapeutics Private Limited expressed gratitude for TDB’s support and stated that the assistance would accelerate clinical translation and commercialization of the company’s innovative CAR-T therapy platform while expanding access to advanced cancer treatment solutions in India. --- For any media inquiries, please reach us at: media-coordinator@tdb.gov.in ******** NKR/FT (Release ID: 2260922) <span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">In a significant step towards strengthening India’s advanced biotechnology and cell therapy ecosystem, the Technology Development Board (TDB), Department of Science &amp; Technology (DST), Government of India, has entered into an agreement with M/s Helix Cell Therapeutics Private Limited, Hyderabad, Telangana for the project titled &ldquo;Generation of Novel Dual Targeting Chimeric Antigen Receptor T Cells to Treat Multiple Myeloma and Conducting Phase I Clinical Trial.&rdquo; The project is being implemented under the Indo-Singapore collaborative framework in partnership with Biocell Innovations, Singapore.</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px"><span style="color:#0d0d0d"><img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image001OLXI.jpg" style="height:237px; width:600px" /></span></span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The project focuses on developing an advanced dual-targeting CAR-T cell therapy for Multiple Myeloma, a debilitating and currently incurable blood cancer. While existing CAR-T therapies targeting BCMA have shown encouraging outcomes in relapsed and refractory patients, the proposed innovation seeks to further improve treatment efficacy and durability of remission by simultaneously targeting both BCMA and CD19 markers expressed on Multiple Myeloma cells.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Under the project, Helix Cell Therapeutics will develop, manufacture, and clinically evaluate next-generation dual-targeting CAR-T cells through a Phase I clinical trial. The therapy is intended for patients who have exhausted multiple lines of treatment and currently have limited therapeutic options available.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">CAR-T cell therapy involves genetically engineering a patient’s own T lymphocytes to specifically identify and destroy cancer cells. The proposed dual-targeting strategy represents a significant advancement over conventional single-marker CAR-T therapies and is expected to improve long-term remission outcomes in difficult-to-treat Multiple Myeloma patients.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">The project aligns with the Government of India’s vision of strengthening indigenous capabilities in advanced biologics, precision medicine, and next-generation healthcare technologies under the broader framework of Aatmanirbhar Bharat. It also reinforces international technology collaboration between India and Singapore in emerging biomedical innovation sectors.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, &ldquo;Advanced cell and gene therapies represent the future of precision healthcare and hold transformative potential for treating complex and previously incurable diseases. Through this Indo-Singapore collaborative project, TDB is supporting indigenous innovation in advanced immunotherapy platforms that can strengthen India’s global position in next-generation biotechnology and affordable healthcare solutions.&rdquo;</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">A representative from Helix Cell Therapeutics Private Limited expressed gratitude for TDB’s support and stated that the assistance would accelerate clinical translation and commercialization of the company’s innovative CAR-T therapy platform while expanding access to advanced cancer treatment solutions in India.</span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px">--- For any media inquiries, please reach us at: media-coordinator@tdb.gov.in</span></span></p> <p style="text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px"><strong>********</strong></span></span></p> <p style="text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:16px"><strong>NKR/FT </strong></span></span></p> " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //